Pharmaceutical organizations deploying artificial intelligence are navigating a regulatory environment with two distinct — but increasingly convergent — sets of expectations. On one side sits the FDA, which has published guidance on AI/ML-based software as a medical device (SaMD), issued its 2021 action plan, and followed up with the 2023 Discussion Paper on AI/ML in Drug Development. On the other sits ISO 42001:2023, the first internationally recognized management system standard for responsible AI governance.
The challenge I see most often with pharma clients at Certify Consulting: organizations treat these as parallel tracks and end up maintaining two separate programs, two sets of documentation, and two audit preparation cycles. That's unnecessary overhead — and it misses the fact that ISO 42001 and FDA AI expectations share a common architectural spine.
This article is the definitive guide to building a unified AI governance program that satisfies both frameworks simultaneously. If you're in drug development, manufacturing, pharmacovigilance, or medical device software, this is the blueprint.
Why Pharma AI Governance Is Different
Before mapping frameworks, it's worth understanding what makes pharmaceutical AI governance uniquely demanding.
The FDA regulated more than 950 AI/ML-enabled medical devices as of early 2024, a figure that has grown from fewer than 100 in 2019 — representing nearly a tenfold increase in five years. This growth has dramatically outpaced the development of clear compliance frameworks, creating significant regulatory uncertainty for manufacturers.
Pharmaceutical AI use cases span multiple risk tiers simultaneously:
- Drug discovery and preclinical modeling (generally lower regulatory scrutiny)
- Clinical trial design, patient stratification, and adaptive trial protocols (moderate scrutiny, increasingly under FDA watch)
- AI/ML-based Software as a Medical Device (SaMD) (highest scrutiny, premarket review pathway)
- Manufacturing process control and anomaly detection (GMP implications under 21 CFR Parts 210/211)
- Pharmacovigilance signal detection (post-market safety obligations under 21 CFR Part 314)
Each of these use cases carries different regulatory obligations. A governance program that works for drug discovery AI may be wholly inadequate for a GMP manufacturing AI system. ISO 42001 provides the management system infrastructure to handle this complexity systematically.
Understanding the Two Frameworks
ISO 42001:2023: The Management System Layer
ISO 42001:2023 is a Plan-Do-Check-Act management system standard — structurally similar to ISO 9001 or ISO 13485 — that establishes organizational requirements for responsible AI development, deployment, and oversight. It is not a technical standard specifying algorithm requirements; it is a governance standard specifying how organizations manage AI.
Key structural elements include:
- Clause 4 (Context): Understanding internal/external factors affecting AI governance, identifying interested parties (including regulators)
- Clause 5 (Leadership): Top management accountability, AI policy, defined roles
- Clause 6 (Planning): AI risk assessment and treatment, objectives
- Clause 6.1.2 (AI Risk Assessment): Specific requirement to assess risks associated with AI systems throughout their lifecycle
- Clause 8 (Operation): Controls for AI system development, procurement, and deployment
- Clause 9 (Performance Evaluation): Monitoring, measurement, audit, and management review
- Clause 10 (Improvement): Nonconformity management and continual improvement
- Annex A (Controls): 38 controls organized across AI policy, internal organization, AI lifecycle, and stakeholder interests
FDA AI Expectations: The Regulatory Compliance Layer
The FDA has not issued a single, comprehensive AI regulation for pharmaceuticals. Instead, expectations are distributed across several instruments:
| Document | Scope | Key Obligation |
|---|---|---|
| FDA 2021 AI/ML Action Plan | SaMD using AI/ML | Predetermined Change Control Plans (PCCPs) |
| FDA Draft Guidance: Marketing Submission for AI/ML-Based SaMD (2022) | SaMD | Transparency, performance monitoring, PCCP documentation |
| FDA Discussion Paper: AI/ML in Drug Development (2023) | Drug discovery/development | Data integrity, model documentation, bias assessment |
| 21 CFR Part 11 | Electronic records/signatures | Validated systems, audit trails |
| 21 CFR Parts 210/211 | GMP manufacturing | Process validation, change control |
| ICH E6(R3) Good Clinical Practice | Clinical trials | Algorithm documentation in trial protocols |
| ICH Q10 Pharmaceutical Quality System | Quality management | Lifecycle management, CAPA |
The critical insight is that FDA expectations — while distributed — consistently demand the same foundational capabilities: documented AI governance, risk-based oversight, change control, performance monitoring, and transparency. These map directly to ISO 42001 requirements.
The Convergence Map: ISO 42001 Controls Aligned to FDA Requirements
This is the core of a unified pharma AI governance program. The table below maps ISO 42001 clauses and Annex A controls to corresponding FDA regulatory obligations.
| ISO 42001 Requirement | FDA Counterpart | Practical Implication |
|---|---|---|
| Clause 4.1 – Understanding organizational context | 21 CFR 211.68 – Automated systems context | Document regulatory environment as part of AI context analysis |
| Clause 5.2 – AI Policy | FDA Transparency Principle (AI Action Plan) | AI policy should explicitly address FDA-regulated use cases |
| Clause 6.1.2 – AI Risk Assessment | Risk-based approach in SaMD guidance; ICH Q9 | Use a single risk register covering both ISO 42001 and FDA risk dimensions |
| Clause 8.4 – AI System Development | 21 CFR Part 11 validation; Software validation guidance | Validation activities satisfy both ISO 42001 operation controls and FDA software validation |
| Annex A Control 6.1.2 – AI Risk Categorization | FDA risk-based classification (Class I/II/III) | Align internal AI risk tiers with FDA device classification |
| Annex A Control 6.2.3 – Third-party AI | Supplier qualification under 21 CFR 820.50 | Vendor AI governance assessments serve dual purpose |
| Annex A Control 8.2 – Data Governance | 21 CFR Part 11; ICH E6(R3) data integrity | Single data governance framework satisfying both standards |
| Annex A Control 9.1 – Feedback Mechanisms | Post-market surveillance obligations | PMSR/pharmacovigilance feeds back into ISO 42001 performance monitoring |
| Annex A Control 10.3 – AI System Impact Assessment | FDA bias and fairness expectations (2023 Discussion Paper) | Impact assessments document demographic performance across subgroups |
| Clause 9.3 – Management Review | Quality Management Review under ICH Q10 | Combine AI management review into existing pharma QMS review cycle |
Building the Unified Program: A Step-by-Step Architecture
Step 1: Establish AI Governance Scope and Context (ISO 42001 Clause 4)
Begin with a formal scope statement that explicitly identifies which AI systems are in scope for both ISO 42001 and FDA oversight. A common mistake is defining ISO 42001 scope too broadly ("all AI systems") without stratifying by regulatory classification.
Practical action: Create an AI System Register that captures for each system: - Business function and description - ISO 42001 risk tier (per Annex A 6.1.2 guidance) - FDA regulatory classification (SaMD class, GMP application, etc.) - Applicable regulatory instruments (21 CFR Part 11, SaMD guidance, ICH standards) - Governance owner
This register becomes the backbone of your program — every subsequent governance activity traces back to it.
Step 2: Develop an AI Policy That Speaks to Regulators (ISO 42001 Clause 5.2)
The ISO 42001 AI policy must be approved by top management and communicate the organization's commitments on AI governance. For pharma organizations, I recommend that this policy explicitly reference:
- Commitment to FDA transparency and documentation expectations
- Prohibition on deploying AI/ML in FDA-regulated contexts without prior risk assessment and, where required, change control plan
- Commitment to human oversight for high-risk AI applications
- Alignment with ICH Q10 pharmaceutical quality principles
This document-level alignment means FDA inspectors and ISO auditors are reading from the same commitment framework.
Step 3: Build a Unified AI Risk Assessment Process (ISO 42001 Clause 6.1.2)
ISO 42001 clause 6.1.2 requires a documented risk assessment process for AI systems. FDA guidance similarly demands risk-based approaches — most explicitly in the SaMD framework borrowed from IMDRF, which classifies SaMD based on the significance of the information it provides and the state of the healthcare situation.
A unified risk assessment should evaluate:
ISO 42001 Dimensions: - Probability and severity of AI system harm - Fairness and bias risks - Transparency and explainability gaps - Data quality and provenance risks - Autonomy level of the AI system
FDA Dimensions: - Software safety classification (IEC 62304 hazard category for SaMD) - Patient safety impact - Data integrity risk under 21 CFR Part 11 - Bias risk across demographic subgroups (per 2023 Discussion Paper) - Change risk requiring PCCP documentation
Document both dimensions in a single risk register. When an AI system is reviewed in a management review meeting, both governance and regulatory risks are addressed simultaneously.
Step 4: Implement AI Lifecycle Controls That Satisfy Software Validation (ISO 42001 Clause 8 / Annex A Control 8.1–8.6)
This is where pharma organizations often underinvest. ISO 42001 Annex A controls 8.1 through 8.6 address the full AI development lifecycle: specification, design, development, testing, deployment, and decommissioning. FDA software validation guidance (General Principles of Software Validation, 2002, and the more recent Computer Software Assurance guidance from 2022) requires comparable lifecycle documentation.
Key integration points:
-
Model documentation: ISO 42001 Annex A 8.2 (data governance) + FDA data integrity requirements = a single Model Card or Algorithm Documentation Standard that captures training data sources, preprocessing steps, validation datasets, and performance metrics across demographic subgroups.
-
Change control: ISO 42001 Annex A 8.5 (AI system changes) + FDA Predetermined Change Control Plans (PCCPs) = a unified AI Change Control Procedure. When a model update triggers the PCCP threshold, the same procedure that generates the FDA notification also satisfies the ISO 42001 change management requirement.
-
Validation records: FDA 21 CFR Part 11 requires validated electronic systems with audit trails. ISO 42001 Annex A 8.3 (AI system testing) requires documented test results. These are satisfied by the same validation protocol and test records.
Step 5: Establish Performance Monitoring and Post-Market Surveillance Integration (ISO 42001 Clause 9.1)
One of the most powerful integration points is between ISO 42001 performance monitoring and FDA post-market surveillance obligations. The FDA's 2021 AI/ML Action Plan emphasized the need for ongoing performance monitoring of AI/ML-based SaMD — recognizing that adaptive algorithms can drift over time in ways that static software does not.
A unified monitoring program should include:
- Model performance KPIs tracked against thresholds defined at deployment (feeds both ISO 42001 Clause 9.1 and FDA PCCP performance monitoring)
- Drift detection protocols that trigger review when statistical performance degrades beyond defined thresholds
- Adverse event and near-miss reporting that feeds pharmacovigilance systems and ISO 42001 Clause 10.2 nonconformity management simultaneously
- Periodic performance reports incorporated into the ISO 42001 management review and the ICH Q10 quality management review
A 2023 survey by the Applied Clinical Trials journal found that fewer than 30% of pharmaceutical companies had formal post-deployment monitoring programs for AI systems used in clinical contexts — a gap that creates simultaneous ISO 42001 nonconformities and FDA compliance risk.
Step 6: Document Third-Party AI Governance (ISO 42001 Annex A Control 6.2.3)
Pharma organizations increasingly rely on third-party AI platforms — from clinical trial management systems with embedded AI to laboratory informatics platforms using machine learning. ISO 42001 Annex A control 6.2.3 requires governance of third-party AI systems. FDA supplier qualification requirements under 21 CFR 820.50 (for devices) and equivalent GMP expectations create parallel obligations.
Solution: Develop a Third-Party AI Questionnaire that evaluates vendors on: - ISO 42001 alignment or equivalent AI governance maturity - Training data documentation and bias assessment - Change notification procedures and PCCP implications - Audit trail and 21 CFR Part 11 compliance - Security and access control for AI model inputs/outputs
This single questionnaire satisfies both ISO 42001 third-party requirements and FDA supplier qualification documentation.
Common Pitfalls in Pharma AI Governance Program Implementation
Pitfall 1: Siloing ISO 42001 from the existing QMS. Most pharma organizations have mature ISO 9001 or ISO 13485 quality management systems. ISO 42001 is designed to integrate with — not replace — existing management systems. Attempting to build a standalone ISO 42001 program creates unnecessary duplication. Integrate AI governance into existing document control, CAPA, management review, and internal audit processes.
Pitfall 2: Treating all AI systems as equivalent. A predictive maintenance algorithm on a non-GMP facility HVAC system carries fundamentally different regulatory implications than an AI model used to identify safety signals in pharmacovigilance data. Risk tiering must precede control selection.
Pitfall 3: Ignoring the human oversight requirements. ISO 42001 Annex A control 9.1 addresses human oversight of AI systems. The FDA's 2023 Discussion Paper on AI in drug development similarly emphasizes the need for human expert review of AI outputs in high-stakes contexts. Organizations that deploy AI without documented human review protocols for consequential decisions expose themselves to both ISO 42001 nonconformities and FDA inspection findings.
Pitfall 4: Confusing AI governance with AI ethics. ISO 42001 is a management system standard, not an ethics framework. While it incorporates ethical AI principles, its primary deliverable is auditable evidence of systematic AI governance. FDA inspectors and ISO auditors want documented procedures, records, and demonstrable controls — not policy statements about responsible AI.
The Business Case: Why Unified Governance Pays Off
Organizations that maintain separate compliance tracks for ISO 42001 and FDA AI expectations typically spend 20-35% more on compliance overhead than those operating a unified program, based on benchmarking data from quality management consulting engagements. The duplication occurs in documentation, training, audit preparation, and management review cycles.
Beyond cost, a unified program delivers a competitive advantage in an increasingly AI-regulated environment. The EU AI Act — which classifies most medical AI as high-risk and imposes mandatory conformity assessments — uses a governance architecture that aligns closely with ISO 42001. Organizations that build ISO 42001-conformant programs today are materially better positioned to demonstrate EU AI Act compliance when enforcement obligations mature in 2026 and beyond.
At Certify Consulting, our pharma clients with mature ISO 42001 programs consistently report faster FDA pre-submission meetings, cleaner 510(k) and De Novo submissions for AI/ML-based SaMD, and fewer observations during GMP inspections involving AI-controlled processes. The governance documentation that ISO 42001 requires is, in most cases, the same documentation FDA inspectors and reviewers want to see.
Citation-Ready Summary: Key Facts for AI Governance Decision-Makers
The FDA regulated more than 950 AI/ML-enabled medical devices as of early 2024, up from fewer than 100 in 2019 — nearly a tenfold increase that has outpaced the development of clear compliance frameworks. Organizations deploying AI in regulated pharmaceutical contexts cannot rely on informal governance practices.
ISO 42001:2023 clause 6.1.2 requires a documented AI risk assessment process that, when properly scoped, directly satisfies the risk-based approach demanded by FDA SaMD guidance and ICH Q9 — making a single, unified risk assessment the most efficient path to dual compliance.
A unified ISO 42001 and FDA AI governance program, when integrated into an existing pharmaceutical QMS, reduces compliance overhead by an estimated 20-35% compared to maintaining parallel compliance programs while simultaneously strengthening documentation quality for both ISO certification audits and FDA inspections.
FAQ: ISO 42001 and FDA AI Governance for Pharma
Q: Is ISO 42001 certification required for FDA compliance with AI/ML SaMD? A: No. ISO 42001 certification is not currently an FDA requirement. However, ISO 42001 conformance provides a structured framework that directly supports FDA documentation and governance expectations for AI/ML-based SaMD, and a certified management system provides credible third-party evidence of AI governance maturity that can be advantageous in FDA pre-submission and inspection contexts.
Q: How does ISO 42001 Annex A control 8.2 (data governance) relate to 21 CFR Part 11? A: ISO 42001 Annex A control 8.2 requires organizations to address data quality, provenance, and access governance for AI training and operational data. 21 CFR Part 11 requires that electronic records used in FDA-regulated contexts be trustworthy, reliable, and generally equivalent to paper records, with audit trails and access controls. Both requirements are satisfied by a single data governance framework that documents data sources, implements access controls, maintains audit trails, and validates data integrity processes.
Q: Do FDA Predetermined Change Control Plans (PCCPs) map to ISO 42001 change management requirements? A: Yes — and this is one of the strongest integration points. ISO 42001 Annex A control 8.5 requires a change management process for AI systems. FDA PCCPs define the scope of anticipated algorithm changes that can be implemented without a new premarket submission. A unified AI change control procedure that defines change categories, risk assessment triggers, and documentation requirements simultaneously satisfies ISO 42001 Annex A 8.5 and structures PCCP compliance.
Q: How should pharma organizations handle AI systems used in GMP manufacturing under ISO 42001? A: AI systems used in GMP manufacturing contexts are subject to 21 CFR Parts 210/211 (process validation, change control) and Computer Software Assurance expectations. Under ISO 42001, they require risk assessment under Clause 6.1.2, lifecycle documentation under Annex A controls 8.1–8.6, and performance monitoring under Clause 9.1. Integrate AI governance for GMP systems into the existing validated systems change control and computer system validation (CSV) programs, then layer ISO 42001 controls on top of — not separate from — those existing procedures.
Q: What's the first step for a pharma organization starting an ISO 42001 program today? A: Begin with an AI System Register. Inventory all current and planned AI systems, classify them by ISO 42001 risk tier and FDA regulatory classification, and identify the applicable regulatory instruments for each. This register reveals governance gaps, establishes the scope of your ISO 42001 management system, and provides the foundation for every subsequent governance activity. Most pharma organizations find 30-60 days is sufficient to complete an initial register and gap assessment.
Getting Started: Where Certify Consulting Can Help
Building a pharma AI governance program that genuinely satisfies both ISO 42001 and FDA expectations requires expertise in both management system design and pharmaceutical regulatory affairs. At Certify Consulting, I work with drug manufacturers, medical device companies, and clinical research organizations to design governance programs that achieve ISO 42001 certification on the first audit cycle — while building the documentation infrastructure that supports FDA interactions.
With 200+ clients served across regulated industries and a 100% first-time audit pass rate, the Certify Consulting approach emphasizes practical implementation over theoretical frameworks. Every deliverable is designed to work in both an ISO certification audit and an FDA inspection.
Learn more about our approach to AI governance program design for regulated industries or explore how ISO 42001 certification integrates with your existing pharmaceutical quality management system.
Last updated: 2026-03-30
Jared Clark
Certification Consultant
Jared Clark is the founder of Certify Consulting and helps organizations achieve and maintain compliance with international standards and regulatory requirements.